Dr. Pinilla-Ibarz Discusses Advancements in CML

Javier Pinilla-Ibarz, MD, PhD: Options to Prolong SurvivalПодробнее

Javier Pinilla-Ibarz, MD, PhD: Principle Treatment Options for Patients With a 17p DeletionПодробнее

Javier Pinilla-Ibarz, MD, PhD: Additional Chemo-ImmunotherapyПодробнее

Experience with Omacetaxine for TKI-Resistant TKI CMLПодробнее

Javier Pinilla-Ibarz, MD, PhD: Treatment Options for Patients With Previously Treated CLLПодробнее

Dr. Pinilla-Ibarz on the Impact of Venetoclax in CLLПодробнее

Treatment-Free Remission in CMLПодробнее

Dr. Pinilla-Ibarz on the Role of Chemotherapy in CLLПодробнее

Javier Pinilla-Ibarz, MD, PhD: Significance of Treat to ProgressionПодробнее

Toxicity for Omacetaxine in CMLПодробнее

Emerging Therapies for CMLПодробнее

Treatment Choice in CMLПодробнее

New trial results and updates on CML, CLL and MDSПодробнее

Dr. Pinilla-Ibarz on Ibrutinib's Efficacy in Treating High-Risk Patients With CLLПодробнее

Tips for Determining the Best CLL Treatment for YouПодробнее

Relapse After CML Treatment DiscontinuationПодробнее

Upfront Treatment in Chronic Myeloid Leukemia (CML)Подробнее

Early Molecular Responses in CMLПодробнее

Monitoring Response to CML TherapyПодробнее